Innovent Announces Phase 2 Clinical Study Of Picankibart (IBI112) In Chinese Patients With Ulcerative Colitis Met Primary Endpoint

(MENAFN - PR Newswire) SAN FRANCISCOand SUZHOU,China, Oct. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, ...Ads Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute